DDInter1848 DDInter899
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trast
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Ticlopidine
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Apixaban